Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and sorafenib in locally advanced or metastatic hepatocellular carcinoma as first-line therapy
2011-006350-87Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of hydroxychloroquine and sorafenib in hepatocellular carcinoma (HCC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Clinical benefit. Started Mar 2012; status: active.
02
Drugs
hydroxychloroquinesorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-006350-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006350-87.